QSAM Biosciences

QSAM Biosciences is a clinical-stage company focused on developing nuclear medicines for the treatment of cancer and related conditions, with a particular emphasis on bone cancer. The company's primary technology is Samarium-153 DOTMP, also known as CycloSam, which is a bone-targeting radiopharmaceutical. CycloSam was developed by IsoTherapeutics Group LLC, recognized leaders in nuclear medicine, and has been assigned to IGL Pharma, Inc., a subsidiary of IsoTherapeutics. The development of CycloSam builds on the expertise of IsoTherapeutics, which also created the FDA-approved radiopharmaceutical Quadramet®, used for pain palliation in cancer patients.